Age-Specific Signatures of Glioblastoma at the Genomic, Genetic, and Epigenetic Levels

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Bozdag, Serdar ^a,b   Li, Aiguo ^a   Riddick, Gregory ^a   Kotliarov, Yuri ^a,c   Baysan, Mehmet ^a   Iwamoto, Fabio M ^a,d   Cam, Margaret C ^a   Kotliarova, Svetlana ^a   Fine, Howard A ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MARQUETTE UNIVERSITY   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; POLYCOMB GROUP PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EXOME; EXON; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETICS; GENOMICS; GLIOBLASTOMA; HUMAN; MATHEMATICAL GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; UPREGULATION;

ADULT; AGE FACTORS; AGED; AGING; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; EPIGENESIS, GENETIC; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYCOMB-GROUP PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 84876895426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062982     Document Type: Article

References (64)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, et al. (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert opinion on investigational drugs 18: 1061-1083.
2. Ohgaki H, Kleihues P, (2005) Epidemiology and etiology of gliomas. Acta neuropathologica 109: 93-108.
3. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
4. Cancer Genome Atlas Research Network, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
5. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, et al. (2006) High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Research 66: 9428-9436.
6. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, et al. (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Research 69: 2091-2099.
7. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America 102: 5814-5819.
8. Mischel PS, Shai R, Shi T, Horvath S, Lu K, et al. (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22: 2361-2373.
9. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, et al. (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 3015-3024.
10. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, et al. (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Research 63: 1602-1607.
11. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
12. Ruano Y, Mollejo M, Ribalta T, Fiaño C, Camacho FI, et al. (2006) Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Molecular cancer 5: 39.
13. Shai R, Shi T, Kremen T, Horvath S, Liau L, et al. (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22: 4918-4923.
14. Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research 66: 159-167.
15. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
16. Lee Y, Scheck A, Cloughesy T, Lai A, Dong J, et al. (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Medical Genomics 1: 52.
17. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, et al. (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. International journal of radiation oncology, biology, physics 26: 239-244.
18. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, et al. (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24: 3871-3879.
19. Halperin EC, Herndon J, Schold SC, Brown M, Vick N, et al. (1996) A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. International journal of radiation oncology, biology, physics 34: 793-802.
20. Stewart LA, (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018.
21. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, et al. (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The lancet oncology 9: 29-38.
22. Noushmehr H, Weisenberger D, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
23. R Development Core Team (2008) R: A Language and Environment for Statistical Computing. Vienna Austria R Foundation for Statistical Computing 1: ISBN 3-0.
24. BioDiscovery I (2009) Locating Significantly Different CNV Regions between Two Groups.
25. Andersen P, Gill R (1982) Cox's regression model for counting processes: a large sample study. The annals of statistics: 1100-1120.
26. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics 34: 267-273.
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102: 15545-15550.
28. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology 4: P3.
29. Zambelli F, Pesole G, Pavesi G, (2009) Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic acids research 37: W247-252.
30. Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, et al. (2010) JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic acids research 38: D105-110.
31. Benjamini Y, Yekutieli D, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Annals of Statistics 29: 1165-1188.
32. Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, et al. (2010) Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain. PLoS Genet 6: e1000952.
33. Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, et al. (2011) Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-Oncology 13: 84-98.
34. Katoh M, (2005) WNT/PCP signaling pathway and human cancer (review). Oncology reports 14: 1583-1588.
35. Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk- Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes. Journal of biomedical informatics.
36. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, et al. (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72: 1217-1222.
37. Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, et al. (2011) The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Research 71: 1647-1657.
38. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger D, et al. (2010) Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Research 20: 440-446.
39. Hernandez D, Nalls M, Gibbs J, Arepalli S, Van Der Brug M, et al. (2011) Distinct DNA methylation changes highly correlated with chronological age in the human brain. Human molecular genetics 20: 1164-1172.
40. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, et al. (2008) PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic acids research 36: D842-846.
41. Paugh B, Qu C, Jones C, Liu Z, Adamowicz-Brice M, et al. (2010) Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. Journal of Clinical Oncology 28: 3061-3068.
42. Noy P, Williams H, Sawasdichai A, Gaston K, Jayaraman PS, (2010) PRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling. Molecular and cellular biology 30: 2120-2134.
43. Stein S, Linn MW, Stein EM, (1989) Psychological correlates of survival in nursing home cancer patients. The Gerontologist 29: 224-228.
44. Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K, (2007) Tolerance to chemotherapy in elderly patients with cancer. Cancer control: journal of the Moffitt Cancer Center 14: 44-56.
45. Tan PK, Downey TJ, Spitznagel EL, Xu P, Fu D, et al. (2003) Evaluation of gene expression measurements from commercial microarray platforms. Nucleic acids research 31: 5676-5684.
46. Ahuja N, Issa JP, (2000) Aging, methylation and cancer. Histology and histopathology 15: 835-842.
47. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP, (1998) Aging and DNA methylation in colorectal mucosa and cancer. Cancer Research 58: 5489-5494.
48. Fraga MF, Esteller M, (2007) Epigenetics and aging: the targets and the marks. Trends in genetics: TIG 23: 413-418.
49. Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, et al. (2011) Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood 118: 2622-2631.
50. Tang M, Chen B, Lin T, Li Z, Pardo C, et al. (2011) Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proceedings of the National Academy of Sciences of the United States of America 108: 15231-15236.
51. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, et al. (2002) c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes & development 16: 2530-2543.
52. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, et al. (2008) N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 27: 3999-4007.
53. Li ZY, Zhu F, Hu JL, Peng G, Chen J, et al. (2011) Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 32: 677-687.
54. Lee H-H, Park K, Choi K (2009) Novel agent that inhibits angiogenesis and metastasis targeting mtor signaling pathway.
55. Liu S, Yang P, Kang H, Lu L, Zhang Y, et al. (2011) NDRG2 induced by oxidized LDL in macrophages antagonizes growth factor productions via selectively inhibiting ERK activation. Biochimica et biophysica acta 1801: 106-113.
56. NicAmhlaoibh R, Shtivelman E, (2001) Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene 20: 270-275.
57. Blanco S, Santos C, Lazo PA, (2007) Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. Molecular and cellular biology 27: 7273-7283.
58. Lux A, Salway F, Dressman HK, Kröner-Lux G, Hafner M, et al. (2006) ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-beta and constitutively active receptor induced gene expression. BMC cardiovascular disorders 6: 13.
59. He LF, Wang TT, Gao QY, Zhao GF, Huang YH, et al. (2011) Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells. Journal of biomedical science 18: 39.
60. Rodríguez P, Higueras MA, González-Rajal A, Alfranca A, Fierro-Fernández M, et al. (2011) The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis. Cardiovascular research 93: 232-241.
61. Chi AS, Sorensen AG, Jain RK, Batchelor TT, (2009) Angiogenesis as a therapeutic target in malignant gliomas. The oncologist 14: 621-636.
62. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG, (2004) Genetic and hypoxic regulation of angiogenesis in gliomas. Journal of neuro-oncology 70: 229-243.
63. Kesari S, (2011) Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Seminars in oncology 38Suppl 4: S2-10.
64. Kreisl TN, Kim L, Moore K, Duic P, Royce C, et al. (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 740-745.